Meta-Analysis
Copyright ©The Author(s) 2021.
World J Transplant. Jul 18, 2021; 11(7): 303-319
Published online Jul 18, 2021. doi: 10.5500/wjt.v11.i7.303
Figure 1
Figure 1 Outline of search methodology, PRISMA 2009 flow diagram.
Figure 2
Figure 2 Pooled risk ratio of focal segmental glomerulosclerosis recurrence between the group that received rituximab (with or without plasmapheresis) and the standard treatment group.
Figure 3
Figure 3 Pooled risk ratio of focal segmental glomerulosclerosis recurrence between patients who did and did not receive plasmapheresis.
Figure 4
Figure 4 Funnel plot evaluating publication bias regarding the effects of rituximab on focal segmental glomerulosclerosis recurrence.
Figure 5
Figure 5 Funnel plot evaluating publication bias regarding the effects of plasmapheresis on focal segmental glomerulosclerosis recurrence.